Who we are
Of the estimated 7,000 known rare diseases, less than 10% have an available treatment option. Our mission is to reduce the impact of rare and devastating diseases by providing urgently needed medicines.
We believe that each person with a rare disease has the right to the best treatment, and we are dedicated to providing this across a range of therapeutic areas. Our core therapy areas include Endocrinology, Oncology and Metabolic.
At Recordati Rare Diseases we have almost 20 years of experience in bringing treatments to those who suffer from little known conditions, including orphan and ultra-orphan diseases.
We work alongside global networks of patients, patient groups, experts, healthcare professionals, scientists, policy makers and regulators to educate communities and improve access.
We are a global leader in rare diseases. We are in around 150 countries and continue to expand our footprint, operations and the number of patients we treat.
We are continuously committed to activities and initiatives within disease communities which support awareness and better research in areas of need, particularly within rare diseases.
Recordati continuously develops new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes.
Commitment, scientific rigour, capability and highly specialized personnel allow the Group to develop new treatments and to build an innovative product pipeline.
MILESTONES
- Agreement to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise
- Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
- Expansion of the rare diseases product portfolio: entry into the endocrinology sector
- Establishment of new subsidiaries in Brazil, Mexico and Colombia
- Entry into the US market rare diseases sector
- Acquisition of product portfolio for the treatment of a number of rare diseases in the US
- Acquisition of Farma-Projekt in Poland, now Recordati Polska
- Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases
